Trending Topic

3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
9 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

Bob Geng, AAAAI 2021: Immunoglobulin Replacement Therapy (Part 1)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 2nd 2021

It was a pleasure to speak with Bob Geng (University of California, San Diego, CA, USA) to give us an overview of immunoglobulin replacement therapy, and subcutaneous human IgG 16.5% in patients with immunodeficiencies.

The abstract entitled ‘Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies‘ (ABSTRACT NUMBER: 238) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.

Part 2 of our discussion can be viewed here.

Questions:

1. Could you give us a brief overview of immunoglobulin replacement therapy in patients with primary immunodeficiencies? (0:18)

2. What are the advantages and limitations of subcutaneous human IgG 16.5% compared with other IgG formulations? (1:48)

Disclosures: Consultant and speaker for Takeda and Grifols; consultant for Koru and Kedrion; provided clinical trial support for Octapharma.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of AAAAI 2021 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup